The 2.3% medical device tax that went into effect this year is posing additional burdens on the industry, which already is being encumbered by a number of regulatory challenges, according to this opinion piece. Companies are being forced to cut jobs, capital budgets and research and development funding because of the tax, which could put the nation's leadership position in the global medtech industry in peril, Henry I. Miller writes.

Full Story:

Related Summaries